Formulary Chapter 11: Eye - Full Chapter
|
11.08.02 |
Ocular diagnostic and peri-operative preparations and photodynamic treatment |
|
|
11.08.02 |
Ocular diagnostic preparations |
|
|
11.08.02 |
Ocular peri-operative drugs |
|
|
11.08.02 |
Subfoveal choroidal neovascularisation |
|
|
11.08.02 |
Vitreomacular traction |
|
|
Bromfenac 900micrograms/ml eye drops

|
Non Formulary

|
Not approved for post-cataract surgery (JFC April 2013) Not approved for prophylaxis of cystoid macular oedema (CMO) in high-risk patients (JFC April 2013) |
Diclofenac Sodium 0.1% eye drops
(Voltarol® Ophtha multidose)
(Ophthalmic)

|
Non Formulary
|
|
Flurbiprofen 0.03% eye drops
(Ocufen®)

|
Non Formulary
|
|
Nepafenac eye drops
(Nevanac®)
(Ophthalmic)

|
Non Formulary
|
|
Key |
Traffic Light Status Information
Status |
Description |
 
|
Medicines that should be initiated by a specialist. Prescribing can be transferred to primary care once the patient has been stabilised.
Shared care: For drugs with regular, ongoing need for monitoring and/or assessment of efficacy or toxicity. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s) (DTC) and approved by the North Central London JFC.
Fact sheet: For drugs with some concerns surrounding safety or efficacy but do not require regular monitoring and/or monitoring of effectiveness/toxicity. |
 
|
Medicines which should normally be prescribed by specialists only (hospital only).
For patients already receiving prescriptions in primary care - continue. No new patients to receive prescriptions in primary care.
See link for the complete NCL Red List https://www.ncl-mon.nhs.uk/wp-content/uploads/2017/08/ncl_red_list.pdf |
 
|
Medicines not recommended for routine use in primary or secondary care.
Medicines, which the North Central London JFC has actively reviewed and does not recommend for use at present due to limited clinical and/or cost effective data. |
|
|